The Podcast by KevinMD cover image

Corporate greed and medical complicity fueled a $250,000 drug

The Podcast by KevinMD

00:00

Regulatory shortcuts and lack of trials

Desai notes Acthar was relabeled without new trials, exploiting earlier approvals and regulatory gaps.

Play episode from 12:06
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app